Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that certain of the western blotting data shown in Figs. 4D and 5B were strikingly similar to data appearing in different form in other articles by different authors. Owing to the fact that the contentious data in the above article had already been published elsewhere prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they agreed with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in Oncology Reports 35: 2151-2158, 2016; DOI: 10.3892/or.2016.4604].

中文翻译：

---

[已撤稿] miR-137 通过靶向 CXCL12 在甲状腺乳头状癌中充当肿瘤抑制因子。

在这篇论文发表后，一位相关读者引起了编辑的注意，图中所示的某些蛋白质印迹数据。4D 和 5B 与不同作者在其他文章中以不同形式出现的数据惊人地相似。由于上述文章中有争议的数据在提交给 Oncology Reports 之前已经在其他地方发表过，编辑决定从期刊上撤回这篇文章。在与作者联系后，他们同意撤回论文的决定。给读者带来的不便，编者深表歉意。【原文发表于 Oncology Reports 35: 2151-2158, 2016；DOI：10.3892/或.2016.4604]。